EPHA1

Across TCGA pan-cancer cohorts, EPHA1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPHA1 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EPHA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPHA1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where EPHA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.895	0.265	.001	30	view →
PDAC	OS	Median	All	0.616	1.000	.012	9	view →
LSCC	DFS	Median	All	0.992	0.876	.020	8	view →
COAD	DFS	Median	III,IV	0.804	1.000	.044	6	view →
UCEC	OS	Tertile	All	0.845	1.000	.015	6	view →
LUAD	DFS	Median	All	0.850	0.949	.008	5	view →
OV	DFS	Median	All	0.598	0.884	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPHA1–HNSC (DFS)

Open the HNSC breakdown →